Literature DB >> 2075083

Prophylactic antibiotics and the hospital budget: controversy for patients and hospital financial strategies?

A Steenhoek1.   

Abstract

Although total drug costs account for only 2 to 3% of the total hospital budget, the management of these costs is of much interest. Total costs can be subdivided into numerous items; each can be influenced to some extent. Such costs are analysed in this article. The Dutch system of hospital budgeting is also described. The way in which (prophylactic) antibiotics can influence budget parameters is described and quantified by an example in gynaecological surgery. It is concluded that the profits of modern pharmacotherapy in the hospitals are earned outside the hospital. Society should realize that these profits must be re-invested to assure a healthy health-care system in the near future.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2075083     DOI: 10.1007/BF01967838

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  1 in total

1.  Single-dose prophylaxis in hysterectomies. An interim analysis.

Authors:  P J Boodt; W P Snijders; R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1990-12-14
  1 in total
  4 in total

1.  Cost of hospital antimicrobial chemotherapy. A method for global cost calculation.

Authors:  I C Gyssens; C A Lennards; Y A Hekster; J W Van der Meer
Journal:  Pharm Weekbl Sci       Date:  1991-12-13

Review 2.  Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.

Authors:  C M Spencer; H M Bryson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

3.  Antimicrobial prophylaxis in hysterectomies: a double-blind, randomized, comparative study of a single dose of piperacillin (2 g) versus a single dose of amoxicillin-clavulanic acid (2.2 g).

Authors:  R Janknegt; J P Schepers; J W Haest; G T Fabius; J J Lohman; A P Smeets
Journal:  Infection       Date:  1993 Jul-Aug       Impact factor: 3.553

Review 4.  Teicoplanin in perspective. A critical comparison with vancomycin.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1991-08-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.